Moderna reports ‘robust’ COVID vaccine response in children aged 6-11

US pharmaceutical giant Moderna reports a “robust neutralizing antibody response” to its COVID-19 vaccine in children aged 6-11, and says that it will submit the trial data to global regulators soon.

“We are encouraged by the immunogenicity and safety profile of mRNA-1273 in children aged 6 to under 12 years and are pleased that the study met its primary immunogenicity endpoints,” chief executive Stephane Bancel says in a statement.

Data from clinical trials with more than 4,700 children in the age range “demonstrate strong immune response… one month after the second dose,” Moderna says in the statement.

The results come after Pfizer said last week that its COVID vaccine is 90% effective in preventing symptomatic disease among children aged 5-11.

Most Popular
If you’d like to comment, join
The Times of Israel Community.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.